{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:22:11Z","timestamp":1793110931803,"version":"4.5.0"},"reference-count":236,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Spanish Network for Research in Infectious Diseases","award":["REIPI RD16\/0016\/0002"],"award-info":[{"award-number":["REIPI RD16\/0016\/0002"]}]},{"name":"Spanish Network for Research in Infectious Diseases","award":["0008"],"award-info":[{"award-number":["0008"]}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cmi.2018.02.009","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T03:13:11Z","timestamp":1518750791000},"page":"S53-S70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"special_numbering":"S2","title":["ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)"],"prefix":"10.1016","volume":"24","author":[{"given":"M.","family":"Reinwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.J.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fort\u00fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Garzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2018.02.009_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.cmi.2018.01.029","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction)","volume":"24","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.02.009_bib2","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.cmi.2017.12.027","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biologic therapies: an infectious diseases perspective (cell surface receptors and associated signaling pathways)","volume":"24","author":"Aguilar-Company","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.02.009_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11864-013-0234-8","article-title":"Chronic myeloid leukemia: overview of new agents and comparative analysis","volume":"14","author":"Jain","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cmi.2018.02.009_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.cmi.2018.02.009_bib6","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor\u2013mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib7","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","article-title":"Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells","volume":"103","author":"Appel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib8","first-page":"1133","article-title":"Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner","volume":"31","author":"Chen","year":"2007","journal-title":"Int J Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib9","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","article-title":"Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling","volume":"12","author":"Chen","year":"2008","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","article-title":"Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens","volume":"36","author":"Fei","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"de Lavallade","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib13","doi-asserted-by":"crossref","first-page":"e2011021","DOI":"10.4084\/mjhid.2011.021","article-title":"Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase","volume":"3","author":"Breccia","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL\u2013positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.02.009_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14639230500236818","article-title":"Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment","volume":"47","author":"Ikeda","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cmi.2018.02.009_bib17","first-page":"e86","article-title":"Imatinib mesylate\u2013related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection","volume":"49","author":"Thia","year":"2008","journal-title":"Singapore Med J"},{"key":"10.1016\/j.cmi.2018.02.009_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12185-009-0386-2","article-title":"Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review","volume":"90","author":"Kang","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3748\/wjg.v19.i8.1318","article-title":"Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor","volume":"19","author":"Lai","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cmi.2018.02.009_bib20","first-page":"3629","article-title":"Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor","volume":"34","author":"Walker","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cmi.2018.02.009_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s12072-008-9099-5","article-title":"Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy","volume":"2","author":"Lakhani","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cmi.2018.02.009_bib22","first-page":"976","article-title":"Development of varicella-zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate","volume":"9","author":"Mattiuzzi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cmi.2018.02.009_bib23","first-page":"e16","article-title":"Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour","volume":"48","author":"Durosinmi","year":"2007","journal-title":"Singapore Med J"},{"key":"10.1016\/j.cmi.2018.02.009_bib24","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/sj.leu.2404758","article-title":"EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia","volume":"21","author":"Leguay","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2018.02.009_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2169\/internalmedicine.44.114","article-title":"Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate","volume":"44","author":"Takashima","year":"2005","journal-title":"Intern Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib26","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1183\/09031936.00025408","article-title":"Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia","volume":"33","author":"Daniels","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2018.02.009_bib27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archinternmed.2008.581","article-title":"Peritoneal tuberculosis after imatinib therapy","volume":"169","author":"Senn","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00277-003-0813-z","article-title":"Pulmonary nocardiosis in a patient with CML relapse undergoing imatinib therapy after bone marrow transplantation","volume":"83","author":"Lin","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib29","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib30","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs. imatinib in patients with newly diagnosed Philadelphia chromosome\u2013positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2018.02.009_bib31","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1002\/cncr.25351","article-title":"Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant","volume":"116","author":"Koren-Michowitz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2018.02.009_bib32","first-page":"55","article-title":"Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors","volume":"10","author":"Reinwald","year":"2015","journal-title":"Biomark Insights"},{"key":"10.1016\/j.cmi.2018.02.009_bib33","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3109\/10428194.2012.656626","article-title":"Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications","volume":"53","author":"Rodriguez","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cmi.2018.02.009_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ajh.21615","article-title":"Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study","volume":"85","author":"Lilly","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cid\/cix325","article-title":"Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation","volume":"65","author":"Prestes","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.tranon.2015.12.004","article-title":"Dasatinib-induced CMV hepatitis in an immunocompetent patient: a rare complication of a common drug","volume":"9","author":"Davalos","year":"2016","journal-title":"Transl Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib37","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.bbmt.2016.06.022","article-title":"Dasatinib-induced colitis after allogeneic stem cell transplantation for Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"22","author":"Aldoss","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4137\/CCRep.S25327","article-title":"Cytomegalovirus-induced hemorrhagic colitis in a patient with chronic myeloid leukemia (chronic phase) on dasatinib as an upfront therapy","volume":"8","author":"Yassin","year":"2015","journal-title":"Clin Med Insights Case Rep"},{"key":"10.1016\/j.cmi.2018.02.009_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-017-1105-1","article-title":"Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature","author":"Knoll","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2018.02.009_bib40","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cmi.2018.02.009_bib41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijid.2014.04.030","article-title":"Pneumocystis jirovecii pneumonia in patients receiving dasatinib treatment","volume":"25","author":"Chang","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12185-015-1788-y","article-title":"Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia","volume":"102","author":"Ando","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib43","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/10428190701671044","article-title":"Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825)","volume":"48","author":"Garcia-Munoz","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cmi.2018.02.009_bib44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Brummendorf","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib46","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cmi.2018.02.009_bib48","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib49","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2018.02.009_bib50","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1182\/blood-2010-06-291922","article-title":"Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib51","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib52","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2018.02.009_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.antiviral.2013.03.006","article-title":"Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in\u00a0vitro","volume":"98","author":"Haasbach","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cmi.2018.02.009_bib55","doi-asserted-by":"crossref","first-page":"e0141903","DOI":"10.1371\/journal.pone.0141903","article-title":"Targeting tuberculosis and HIV infection\u2013specific regulatory T cells with MEK\/ERK signaling pathway inhibitors","volume":"10","author":"Lieske","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.02.009_bib56","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbrc.2015.01.160","article-title":"Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-alpha production and endotoxin shock","volume":"458","author":"Du","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cmi.2018.02.009_bib57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.chom.2016.04.024","article-title":"Identifying the target cells and mechanisms of merkel cell polyomavirus infection","volume":"19","author":"Liu","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cmi.2018.02.009_bib58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s13071-015-1023-y","article-title":"Repurposing of anticancer drugs: in\u00a0vitro and in\u00a0vivo activities against Schistosoma mansoni","volume":"8","author":"Cowan","year":"2015","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.cmi.2018.02.009_bib59","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib60","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1158\/1078-0432.CCR-14-2667","article-title":"Contribution of beta-HPV infection and UV damage to rapid-onset cutaneous squamous cell carcinoma during BRAF-inhibition therapy","volume":"21","author":"Cohen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cmi.2018.02.009_bib61","doi-asserted-by":"crossref","first-page":"e110478","DOI":"10.1371\/journal.pone.0110478","article-title":"Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection","volume":"9","author":"Frouin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.02.009_bib62","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib63","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib64","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/annonc\/mdt587","article-title":"Differential influence of vemurafenib and dabrafenib on patients\u2019 lymphocytes despite similar clinical efficacy in melanoma","volume":"25","author":"Schilling","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib65","doi-asserted-by":"crossref","first-page":"e0124590","DOI":"10.1371\/journal.pone.0124590","article-title":"Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection","volume":"10","author":"Sondermann","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.02.009_bib66","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4103\/0973-1482.136039","article-title":"Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis","volume":"11","author":"Marsico","year":"2015","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.cmi.2018.02.009_bib67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.009_bib68","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cmi.2018.02.009_bib69","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00277-014-2104-2","article-title":"Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib","volume":"93","author":"Vergote","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib70","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib71","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib72","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib73","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2015.04.005","article-title":"A\u00a0phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1\/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"138","author":"Coleman","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib74","doi-asserted-by":"crossref","first-page":"32258","DOI":"10.18632\/oncotarget.15632","article-title":"Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cmi.2018.02.009_bib75","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3892\/mco.2016.978","article-title":"Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma","volume":"5","author":"Cebollero","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib76","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib77","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib78","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2018.02.009_bib79","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib81","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib82","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib83","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib84","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib85","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.009_bib86","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib87","article-title":"Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib","volume":"2016","author":"Okamoto","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib88","article-title":"Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia","author":"Stankowicz","year":"2018","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.cmi.2018.02.009_bib89","doi-asserted-by":"crossref","first-page":"ofw261","DOI":"10.1093\/ofid\/ofw261","article-title":"Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib","volume":"4","author":"Messina","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib90","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","article-title":"Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib","volume":"128","author":"Ahn","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24890","article-title":"Ibrutinib-associated Pneumocystis jirovecii pneumonia","author":"Lee","year":"2017","journal-title":"Am J Hematol"},{"issue":"15 suppl","key":"10.1016\/j.cmi.2018.02.009_bib92","first-page":"e19025","article-title":"Integrated infectious toxicity analysis of the BTK inhibitor ibrutinib","volume":"34","author":"Pauff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib93","first-page":"27","article-title":"Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia","volume":"21","author":"Arthurs","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.cmi.2018.02.009_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmal.2018.01.003","article-title":"Cerebral aspergillosis: an emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?","author":"Gaye","year":"2018","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.cmi.2018.02.009_bib95","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00277-017-2944-7","article-title":"Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia","volume":"96","author":"Chan","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib96","doi-asserted-by":"crossref","first-page":"548","DOI":"10.4143\/crt.2016.110","article-title":"Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia","volume":"49","author":"Lutz","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.cmi.2018.02.009_bib97","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system","volume":"15","author":"Raisch","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2018.02.009_bib98","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib99","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2017-08-764712","article-title":"How I treat CLL patients with ibrutinib","volume":"131","author":"Brown","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib101","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cmi.2018.02.009_bib102","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","article-title":"Oncogenic PI3K and its role in cancer","volume":"18","author":"Samuels","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib103","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib104","unstructured":"Zydelig (idelalisib). Summary of product characteristics. Gilead Sci. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/3329\/smpc."},{"key":"10.1016\/j.cmi.2018.02.009_bib105","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib106","doi-asserted-by":"crossref","first-page":"e94496","DOI":"10.1371\/journal.pone.0094496","article-title":"Identification of a role for the PI3K\/AKT\/mTOR signaling pathway in innate immune cells","volume":"9","author":"Xie","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.02.009_bib107","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1158\/1078-0432.CCR-14-2424","article-title":"Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on phase I clinical trials","volume":"21","author":"Rafii","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cmi.2018.02.009_bib108","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib109","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib110","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1182\/blood.V128.22.5583.5583","article-title":"Temporal profiles of lymphocyte subsets and the correlation with infectious events in idelalisib-treated patients","volume":"128","author":"Sharman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib111","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib112","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib113","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib114","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008722","article-title":"Multiple functions of BCL-2 family proteins","volume":"5","author":"Hardwick","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.cmi.2018.02.009_bib115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.38966","article-title":"Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-alpha production","volume":"67","author":"Zhan","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.009_bib116","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib117","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib118","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.jfas.2008.12.006","article-title":"Diagnosis and treatment of forefoot disorders. Section 4. Tailor\u2019s bunion","volume":"48","author":"Clinical Practice Guideline Forefoot Disorders Panel","year":"2009","journal-title":"J\u00a0Foot Ankle Surg"},{"key":"10.1016\/j.cmi.2018.02.009_bib119","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma","volume":"83","author":"Agarwal","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2018.02.009_bib120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2006.06206.x","article-title":"The role of Janus kinases in haemopoiesis and haematological malignancy","volume":"134","author":"Khwaja","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib121","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.cmi.2018.02.009_bib122","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.cmi.2018.02.009_bib123","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O\u2019Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib124","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.immuni.2012.03.016","article-title":"Inborn errors of human JAKs and STATs","volume":"36","author":"Casanova","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.cmi.2018.02.009_bib125","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib126","first-page":"184","article-title":"The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective","volume":"1","author":"Staerk","year":"2012","journal-title":"JAKSTAT"},{"key":"10.1016\/j.cmi.2018.02.009_bib127","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib128","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib129","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.009_bib131","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib132","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","article-title":"Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib133","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/ajt.13181","article-title":"Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients","volume":"15","author":"Vincenti","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib134","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.009_bib135","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2018.02.009_bib136","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1200\/JCO.2015.61.4578","article-title":"Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for\u00a0whom therapy with gemcitabine has failed","volume":"33","author":"Hurwitz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib137","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in\u00a0vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Parampalli","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib138","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.13519","article-title":"JAK inhibition induces silencing of T helper cytokine secretion and a profound reduction in T regulatory cells","volume":"171","author":"Keohane","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2018.02.009_bib139","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in\u00a0vitro and in\u00a0vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib140","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK inhibition impairs NK cell function in myeloproliferative neoplasms","volume":"75","author":"Schonberg","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.cmi.2018.02.009_bib141","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Maeshima","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.009_bib142","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2018.02.009_bib143","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.009_bib144","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs. best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2018.02.009_bib145","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3109\/10428194.2014.969260","article-title":"Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis","volume":"56","author":"Jung","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cmi.2018.02.009_bib146","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al Ali","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.02.009_bib147","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clml.2014.08.003","article-title":"A\u00a0phase I\/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cmi.2018.02.009_bib148","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib149","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","article-title":"Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis","volume":"28","author":"Caocci","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2018.02.009_bib150","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.dld.2017.03.004","article-title":"Occult hepatitis B infection reactivation after ruxolitinib therapy","volume":"49","author":"Perricone","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib151","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","article-title":"An opportunistic infection associated with ruxolitinib, a novel Janus kinase 1,2 inhibitor","volume":"143","author":"Wysham","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2018.02.009_bib152","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-204950","article-title":"Pneumocystis jirovecii pneumonitis complicating ruxolitinib therapy","volume":"2014","author":"Lee","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cmi.2018.02.009_bib153","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJMc1302895","article-title":"Bilateral toxoplasmosis retinitis associated with ruxolitinib","volume":"369","author":"Goldberg","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib154","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/1756-0500-5-552","article-title":"Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report","volume":"5","author":"Colomba","year":"2012","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.cmi.2018.02.009_bib155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib156","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib157","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.009_bib158","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cmi.2018.02.009_bib159","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/annrheumdis-2014-207178","article-title":"Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs","volume":"75","author":"Charles-Schoeman","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib160","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib161","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib162","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.009_bib164","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.humimm.2016.12.005","article-title":"Janus kinase inhibition for immunosuppression in solid organ transplantation: is there a role in complex immunologic challenges?","volume":"78","author":"Moore","year":"2017","journal-title":"Hum Immunol"},{"key":"10.1016\/j.cmi.2018.02.009_bib165","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib166","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cmi.2018.02.009_bib167","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrm1018","article-title":"Tor signalling in bugs, brain and brawn","volume":"4","author":"Jacinto","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cmi.2018.02.009_bib168","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2018.02.009_bib169","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.12756","article-title":"mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging","volume":"1346","author":"Perl","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cmi.2018.02.009_bib170","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cmi.2018.02.009_bib171","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","article-title":"Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway","volume":"10","author":"Manning","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.cmi.2018.02.009_bib172","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.cmi.2018.02.009_bib173","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"key":"10.1016\/j.cmi.2018.02.009_bib174","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","article-title":"Targeting the mTOR signaling network in cancer","volume":"13","author":"Chiang","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib175","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: a molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.cmi.2018.02.009_bib176","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.cmi.2018.02.009_bib177","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib178","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/gad.1617608","article-title":"Hypoxia regulates TSC1\/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling","volume":"22","author":"DeYoung","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.cmi.2018.02.009_bib179","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib181","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib182","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejim.2006.07.017","article-title":"Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex","volume":"18","author":"Herry","year":"2007","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib183","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi\u2019s sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib184","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/01.TP.0000115344.18025.0B","article-title":"Conversion to sirolimus: a successful treatment for posttransplantation Kaposi\u2019s sarcoma","volume":"77","author":"Campistol","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.009_bib185","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","article-title":"Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer","volume":"29","author":"Miller","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib186","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","article-title":"Role of VHL gene mutation in human cancer","volume":"22","author":"Kim","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib187","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib188","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.009_bib189","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2018.02.009_bib190","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib191","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib192","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.009_bib193","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib194","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North central cancer treatment group study","volume":"23","author":"Galanis","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib195","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cncr.21265","article-title":"CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium","volume":"104","author":"Margolin","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2018.02.009_bib196","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.cmi.2018.02.009_bib197","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1002\/gepi.20474","article-title":"The challenge of detecting epistasis (G\u00a0\u00d7 G interactions). Genetic Analysis Workshop 16","volume":"33","author":"An","year":"2009","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.cmi.2018.02.009_bib198","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/ajt.13151","article-title":"Evolving perspectives of mTOR complexes in immunity and transplantation","volume":"15","author":"Fantus","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib199","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/TP.0b013e318276a1ef","article-title":"Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients","volume":"95","author":"Havenith","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.009_bib200","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/tid.12601","article-title":"Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients","volume":"18","author":"Pascual","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.009_bib201","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor\u2013based regimen versus a cni-based regimen: a systematic review and meta-analysis of randomized, controlled trials","volume":"12","author":"Mallat","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2018.02.009_bib202","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.it.2014.11.005","article-title":"Regulation of T cells by mTOR: the known knowns and the known unknowns","volume":"36","author":"Pollizzi","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.cmi.2018.02.009_bib203","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1600-6143.2010.03407.x","article-title":"Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques","volume":"11","author":"Turner","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib204","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fimmu.2012.00228","article-title":"Akt and mTOR in B cell activation and differentiation","volume":"3","author":"Limon","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2018.02.009_bib205","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/01.TP.0000056639.74982.F9","article-title":"Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil","volume":"75","author":"van Gelder","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.009_bib206","first-page":"17","article-title":"Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity","volume":"229","author":"Yang","year":"2014","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.cmi.2018.02.009_bib207","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0014-5793(03)00828-7","article-title":"Rapamycin inhibits GM-CSF-induced neutrophil migration","volume":"550","author":"Gomez-Cambronero","year":"2003","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cmi.2018.02.009_bib208","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.4049\/jimmunol.171.12.6846","article-title":"Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway","volume":"171","author":"Gomez-Cambronero","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2018.02.009_bib209","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1165\/rcmb.2008-0290OC","article-title":"Participation of mammalian target of rapamycin complex 1 in Toll-like receptor 2\u2013 and 4\u2013induced neutrophil activation and acute lung injury","volume":"41","author":"Lorne","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.cmi.2018.02.009_bib210","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.devcel.2010.11.004","article-title":"mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion","volume":"19","author":"Liu","year":"2010","journal-title":"Dev Cell"},{"key":"10.1016\/j.cmi.2018.02.009_bib211","doi-asserted-by":"crossref","first-page":"e10643","DOI":"10.1371\/journal.pone.0010643","article-title":"Accelerated wound healing by mTOR activation in genetically defined mouse models","volume":"5","author":"Squarize","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.02.009_bib212","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1042\/BST20130032","article-title":"Immune responses of macrophages and dendritic cells regulated by mTOR signalling","volume":"41","author":"Katholnig","year":"2013","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.cmi.2018.02.009_bib213","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tips.2014.11.004","article-title":"Current treatment strategies for inhibiting mTOR in cancer","volume":"36","author":"Chiarini","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.cmi.2018.02.009_bib214","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1038\/bjc.2013.278","article-title":"Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors","volume":"108","author":"Kaymakcalan","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cmi.2018.02.009_bib215","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2012.04004.x","article-title":"Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer","volume":"12","author":"Campbell","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib216","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.009_bib217","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2012.45.6376","article-title":"Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus","volume":"31","author":"Hoogendijk-van den Akker","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.02.009_bib218","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/TP.0b013e3182247ae2","article-title":"Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial","volume":"92","author":"Alberu","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.009_bib219","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation","volume":"17","author":"Campistol","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2018.02.009_bib220","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.cmi.2018.02.009_bib221","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/ndt\/gfh322","article-title":"Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients","volume":"19","author":"Budde","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib222","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.009_bib223","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/ajt.14048","article-title":"Early conversion to prednisolone\/everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled MECANO trial","volume":"17","author":"Bemelman","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib224","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial","volume":"17","author":"de Fijter","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib225","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/01.TP.0000118413.92211.B6","article-title":"Sirolimus-associated pulmonary toxicity","volume":"77","author":"Pham","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.009_bib226","first-page":"297","article-title":"Interstitial pneumonitis as an adverse reaction to mTOR inhibitors","volume":"33","author":"Molas-Ferrer","year":"2013","journal-title":"Nefrologia"},{"key":"10.1016\/j.cmi.2018.02.009_bib227","doi-asserted-by":"crossref","first-page":"e65166","DOI":"10.1371\/journal.pone.0065166","article-title":"Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis","volume":"8","author":"Qi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.02.009_bib228","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2018.02.009_bib229","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1097\/00007890-199911270-00016","article-title":"Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.009_bib230","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Rapamune US Study Group","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.009_bib231","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.009_bib232","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/TP.0b013e318291a269","article-title":"A\u00a0randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients","volume":"95","author":"Flechner","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.009_bib233","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.009_bib234","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/07357907.2016.1242009","article-title":"Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer","volume":"34","author":"Garcia","year":"2016","journal-title":"Cancer Invest"},{"key":"10.1016\/j.cmi.2018.02.009_bib235","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12328-013-0371-4","article-title":"Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus Carrier","volume":"6","author":"Mizuno","year":"2013","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.cmi.2018.02.009_bib236","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4254\/wjh.v5.i1.43","article-title":"Hepatitis B reactivation related to everolimus","volume":"5","author":"Sezgin Goksu","year":"2013","journal-title":"World J Hepatol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18301824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18301824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T07:42:14Z","timestamp":1719819734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18301824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":236,"alternative-id":["S1198743X18301824"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2018.02.009","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2018.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}